Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.48 |
| ▸ | CYP26B1 | Q9NR63 | 5/20 | 0.48 |
| ▸ | RXRB | P28702 | 7/20 | 0.47 |
| ▸ | RARB | P10826 | 6/20 | 0.47 |
| ▸ | RARG | P13631 | 6/20 | 0.47 |
| ▸ | RARA | P10276 | 5/20 | 0.47 |
| ▸ | RXRG | P48443 | 4/20 | 0.43 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7773852 | 0.86 | RXRA (0.38) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6733629 | 0.84 | RXRA (0.53) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6736308 | 0.82 | RXRA (0.47) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6736305 | 0.82 | RXRA (0.47) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6733069 | 0.82 | RXRA (0.50) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL7769514 | 0.81 | RXRA (0.49) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6729166 | 0.78 | RXRA (0.59) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6736906 | 0.77 | RXRA (0.45) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6737119 | 0.74 | RXRA (0.55) | RXRACYP26A1CYP26B1RXRBRARB | |
| SCHEMBL6730217 | 0.73 | RXRA (0.57) | RXRACYP26A1CYP26B1RXRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | claimed |
| EP-0823903-B1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CT INTERNAT DE RECH S (FR) | 2001-07-18 | — | — | EP | claimed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | claimed |
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | disclosed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | TYR, MITF, CYP1B1 | RXRA 407/4885CYP26A1 144/4885CYP26B1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.